Actuate Therapeutics Inc.
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing elraglusib, a GSK-3β inhibitor targeting NF-kB and DNA damage response pathways in difficult-to-treat cancers.
10-QNov 13Latest SEC filing
Nov 13Latest story
November 2026
October 2026
August 2026
July 2026